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INTRODUCTION
The MET, which is encoded by the met proto-oncogene, is
a transmembrane glycoprotein of 190 kDa (1). The ligand of
MET is a hepatocyte growth factor/scatter factor (HGF/SF),
which has diverse biologic functions including mitogenic (2),
motogenic (3) and morphogenetic (4) activities on a variety
of epithelial cells, including renal tubular cells (5, 6). HGF/SF
has been also reported to promote the invasive properties of
cultured renal cell carcinoma (RCC) cells in vitro (7), sug-
gesting a possible role of MET in the progression of RCC.
The evidences implicating the mutation of met in the devel-
opment of hereditary papillary renal carcinoma have been
obtained (8-10). A gene associated with the hereditary pap-
illary renal carcinoma and a small proportion of sporadic pap-
illary RCC was mapped to a region encompassing the met
locus (8), and the sequencing revealed germline met mutations
in affected individuals (9). Recently, overexpression of MET
protein has been noted in sporadic papillary RCC (11), in
which the mutation of met has been known to be rarely detect-
ed. The expression of MET in sporadic RCC related to the
subtypes, however, has not been well elucidated. 
Here, we evaluated the expression of MET by the immuno-
histochemistry in RCC with various subtypes, urothelial car-
cinoma of renal pelvis, and renal oncocytoma. We also ana-
lyzed the correlation of MET expression with clinicopatho-
logic parameters in clear cell RCC, the most common type
of RCC.
MATERIALS AND METHODS
Cases obtained by radical nephrectomy due to renal neo-
plasm were identified from the files of the Department of
Pathology, reviewing surgical pathology reports and reexam-
ining all available glass slides of the cases. The RCC classifi-
cation system proposed by World Health Organization Clas-
sification of Tumours in 2004 was adopted (12). Cases includ-
ed clear cell RCC (n=96), papillary RCC (n=20) including
type 1 (n=13) and type 2 (n=7), divided according to the
Delahunt and Eble classification (13), chromophobe renal
carcinoma (n=24) including typical (n=18) and eosinophilic
variant (n= 6), divided according to Thoenes et al. (14), col-
lecting duct carcinoma (n=5), urothelial carcinoma of renal
pelvis (n=25), and renal oncocytoma (n=12). Clinical data
of the patients with RCC were retrieved. Medical records were
reviewed for demographic and follow-up informations. Any
cases were excluded if there was family history of RCC or
multiple tumors. Macroscopic information pertaining to the
tumor size, extent of the tumor, and cystic change was ob-
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MET Expression in Sporadic Renal Cell Carcinomas
Although germline mutations of met proto-oncogene on human chromosome 7q31-
34 have been known as useful molecular markers of hereditary papillary renal cell
carcinoma (RCC), the expression of MET, a product of met proto-oncogene, has
not been fully studied in sporadic RCC, along with its clinical significance. We inves-
tigated the expression of MET by immunohistochemistry in 182 cases of renal neo-
plasm encompassing 145 RCC, 25 urothelial carcinomas of renal pelvis, and 12
oncocytomas. MET was diffusely and strongly expressed in 90% of papillary RCC,
all collecting duct carcinomas, and 92% of urothelial carcinomas of renal pelvis. On
the contrary, clear cell RCC, chromophobe RCC, and oncocytomas were negative
or focally positive for MET expression. In clear cell RCC, MET expression was posi-
tively correlated with high nuclear grade, presence of infiltrative growth, tumoral
necrosis, papillary architecture, sarcomatoid component, tumoral involvement of
the renal pelvis or ureter, involvement of the calyx, and lymphatic invasion. In con-
clusion, diffuse and strong expression of MET in papillary RCC and collecting duct
carcinoma might be helpful in discriminating from the other subtypes of RCC with
tubular or papillary growth. In case of MET expression observed in clear cell RCC,
it might correlate with those clinicopathological parameters implying aggressive
behavior. 
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tained from the pathology reports. The tumor stage at presen-
tation was based on all available clinicopathologic informa-
tions according to the scheme proposed by the American Joint
Committee on Cancer (15). 
Hematoxylin and eosin-stained histologic slides from all
cases were reviewed by two pathologists in a blinded inde-
pendent fashion. A nuclear grade was assigned to each tumor
using the grading system of Fuhrman et al. (16). 
Immunohistochemical staining was performed on one or
two representative blocks per each case with rabbit polyclonal
antibody against human MET protein (1:80, Novocastra,
Newcastle, U.K.) using the two-step, peroxidase-labeled
EnVision+TM system (DAKO, Glostrup, Denmark) after anti-
gen retrieval using two times of heating for 5 min in an 800-
W microwave oven to maintain the temperature of the buffer
(0.01 M citrate, pH 6.0) at about 100℃. Diaminobenzidine
was used as a chromogen. Positive internal controls and neg-
ative controls (omission of primary antibody) were evaluat-
ed simultaneously. It was considered positive if the intercel-
lular or basolateral membranes with or without cytoplasm
were stained in more than 5% of tumor cells. And it was
graded as 1+when less than 50% of tumor cells were stained,
and as 2+ when 50% or more of tumor cells were stained.
The intensity of the staining was graded as weak, moderate,
Fig. 1. Immunohistochemical staining for MET shows strong reactivity in the cell membrane with cytoplasmic staining in papillary renal cell
carcinoma (A, ×200), collecting duct carcinoma (B, ×400) and urothelial carcinoma of renal pelvis (C, ×400). No reactivity was found in
55% of clear cell renal cell carcinomas (D, ×200).
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and strong. There were no cases demonstrating less than 50%
of tumor cells stained with strong intensity or demonstrating
more than 50% of tumor cells stained with weak intensity. 
Statistical analysis was performed by use of the Fisher’s exact
test, Student t-test and analysis of variances at the 5% level
in SPSS 10.0 software (SPSS Inc., Chicago, Illinois, U.S.A.).
RESULTS
Expression of MET in renal neoplasms 
In normal kidney, MET expression was limited to the epi-
thelial cells in the proximal convoluted tubule, the collect-
ing duct, and the loop of Henle. The glomeruli, distal con-
voluted tubule, and the stroma were consistently negative
for MET expression. 
Strong and diffuse MET expression (2+), characteristically
localized in the intercellular membranes or basolateral por-
tions with or without cytoplasm of tumor cells, was observed
in 90% of papillary RCC, all cases of collecting duct carci-
noma, and 92% of urothelial carcinoma (Table 1, Fig. 1A-C).
On the contrary, in clear cell RCC and chromophobe RCC,
there was no case with diffuse strong MET expression. There
was no expression of MET in 55% of clear cell RCC (Fig. 1D)
and 92% of chromophobe RCC. Just focal MET expression
(1+) with similar localization was found in 45% of clear cell
RCC and 8% of chromophobe RCC (Fig. 2A), but no cases
of oncocytoma. There was only faint cytoplasmic staining
without membranous accentuation observed in less than
5% of tumor cells in 11 cases of oncocytoma (Fig. 2B) and
11 cases of chromophobe RCC, even after the endogenous
biotin blocking. 
Correlation of MET expression with clinicopathological
parameters in clear cell RCC
Focal MET expression (1+) was found in 43 out of 96 clear
cell RCC. MET expression in clear cell RCC was correlated
with high nuclear grade (p<0.001), presence of infiltrative
growth (p<0.001), tumoral necrosis (p<0.001), papillary archi-
tecture (p=0.005), sarcomatoid component (p<0.030), tumoral
involvement of the renal pelvis or ureter (p=0.014), involve-
ment of the calyx (p=0.016), and lymphatic invasion (p=
MET Negative 2+ 1+ Total
Renal cell carcinomas 77 (53%) 45 (31%) 23 (16%) 145
Conventional renal  53 (55%) 43 (45%) 0 (0%) 96
carcinoma
Papillary renal carcinoma 2 (10%) 0 (0%) 18 (90%) 20
Type 1 1 (8%) 0 (0%) 12 (92%) 13
Type 2 1 (14%) 0 (0%) 6 (86%) 7
Chromophobe renal  22 (11*) (92%) 2 (8%) 0 (0%) 24
carcinoma
Typical type 16 (89%) 2 (11%) 0 (0%) 18
Eosinophilic type 6 (100%) 0 (0%) 0 (0%) 6
Collecting duct carcinoma 0 (0%) 0 (0%) 5 (100%) 5
Urothelial carcinoma of   2 (8%) 0 (0%) 23 (92%) 25
renal pelvis
Oncocytoma 12 (11*) (100%) 0 (0%) 0 (0%) 12
Table 1. The expression of MET in renal neoplasms
*, faint cytoplasmic staining.
1+, reactive in <50% of tumor cells; 2+, reactive in ≥50% of tumor cells.
Fig. 2. Immunohistochemical staining for MET shows focal and weak reactivity in the cell membrane with or without cytoplasmic staining
in chromophobe renal cell carcinoma (A, ×400). Focal and weak cytoplasmic staining is observed in less than 5% of tumor cells in 11 cases
of renal oncocytoma (B, ×400).
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0.016) (Table 2). MET expression was more frequently found
in the tumors of advanced stage (stage 3 or 4) than in local-
ized stage (stage 1 or 2), although it was not statistically sig-
nificant.
DISCUSSION
The relationship between MET expression and subtypes
of RCC has not been well elucidated in sporadic RCC. In
present study, diffuse and strong MET expression was found
in papillary RCC and collecting duct carcinoma, whereas
clear cell RCC and chromophobe RCC showed negative or
focal cytoplasmic staining. Inoue et al. (17) reported that all
20 RCC with tubulo-papillary histology showed positive
staining for MET, and 98% (88 out of 90) of clear cell RCC
showed negative or focal staining, which well corresponds to
our result. There was a few reports showing no association
with the subtypes of RCC and MET expression (18, 19). The
number of cases in those reports, however, is thought to be
relatively small to reveal the relationship of the subtypes of
RCC and MET expression. Diffuse and strong immunoex-
pression of MET in papillary RCC and collecting duct car-
cinoma might be helpful in discriminating from the other
subtypes of RCC with tubulo-papillary growth.
Renal neoplasm has been a major subject of cytogenetic
and molecular genetic studies. Papillary RCC was character-
ized by trisomy of chromosomes 7, 16, 17 and loss of Y chro-
mosome in male patients in cytogenetics (20). A germline
mutation of met gene of 7q31 has been detected in patients
with hereditary papillary renal carcinoma (8) as well as a small
portion of sporadic papillary RCC (9). In present study, the
over expression of MET was detected in 90% of sporadic pap-
illary RCC by the method of immunohistochemistry, which
was much higher than the result of the previous study using
molecular method that identified met mutations in 13% of
sporadic RCC (9). Our result is consistent with that of a recent
study reporting MET over expression in 80% of sporadic RCC
by the immunohistochemistry (11). Trisomy of chromosome
7 has been reported in 95% of sporadic RCC (20), and it may
result in an increased met mRNA copy number, as described
by Glukhova et al. (21). The increased met mRNA copy num-
ber may lead to MET overexpression in protein level. The
significance of chromosome 7 trisomy observed in sporadic
papillary RCC is that the trisomy may serve to increase the
dosage of the met allele. The tumorigenesis by met is known
to be quantitatively related to its level of activation (22). Thus,
it appears that in addition to met mutation, MET overexpres-
sion contributes to the sporadic RCC.
Regarding the subtypes of papillary RCC, no significant
difference of MET expression between two subtypes was
observed in our study. In type 1 and type 2 papillary RCC,
92% and 86% of the cases, respectively, showed immuno-
expression of MET (Table 1). Delahunt and Eble proposed
Clinicopathological
parameters
MET
Negative Positive
Total p-value
Fuhrman’s nuclear grade
1 18 (82%) 4 (18%) 22
2 24 (71%) 10 (29%) 34
3 10 (42%) 14 (58%) 24
4 1 (6%) 15 (94%) 16 p<0.001
Infiltrative growth
- 48 (67%) 24 (33%) 72
+ 5 (21%) 19 (79%) 24 p<0.001
Tumor necrosis
- 47 (69%) 21 (31%) 68
+ 6 (21%) 22 (79%) 28 p<0.001
Papillary architecture
- 48 (62%) 29 (38%) 77
+ 5 (26%) 14 (74%) 19 p=0.005
Pelvic or ureteral involvement
- 52 (59%) 36 (41%) 88
+ 1 (13%) 7 (88%) 8 p=0.014
Calyceal involvement
- 53 (56%) 38 (42%) 91
+ 0 (0%) 5 (100%) 5 p=0.016
Lymphatic invasion
- 49 (61%) 32 (40%) 81
+ 4 (27%) 11 (73%) 15 p=0.016
Sarcomatoid component
- 52 (58%) 37 (42%) 89
+ 1 (14%) 6 (86%) 7 p=0.030
Capsular invasion
- 49 (56%) 38 (44%) 87
+ 4 (44%) 5 (46%) 9 p=0.368
Tumoral infiltration to the perinephric fat
- 49 (58%) 35 (42%) 84
+ 4 (33%) 8 (67%) 12 p=0.094
Renal vein invasion
- 50 (58%) 36 (42%) 86
+ 3 (30%) 7 (70%) 10 p=0.087
Cystic change
- 21 (51%) 20 (49%) 41
+ 32 (58%) 23 (42%) 55 p=0.319
The initial extent of primary tumor (T)
1 29 (59%) 20 (41%) 49
2 18 (55%) 15 (46%) 33
3 6 (43%) 8 (57%) 14 p=0.554
4 0 (0%) 0 (0%) 0
The initial status of node metastasis (N)
0 52 (56%) 41 (44%) 93
1 0 (0%) 1 (100%) 1
2 1 (50%) 1 (50%) 2 p=0.529
Distant metastasis at the time of diagnosis (M)
0 53 (57%) 40 (43%) 93
1 0 (0%) 3 (100%) 3 p=0.086
Pathologic stage
I 29 (62%) 18 (38%) 47
II 17 (55%) 14 (45%) 31
III 6 (46%) 7 (54%) 13
IV 1 (20%) 4 (80%) 5 p=0.291
Table 2. The relationship between clinicopathologic parame-
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subdividing papillary RCC into two subtypes, type 1 with
small cells and pale cytoplasm and type 2 with large cells
and eosinophilic cytoplasm (13). In the study by Lubensky
et al. (23), all 6 sporadic RCC with met mutations demon-
strated type 1, whereas 10 papillary RCC without met muta-
tions demonstrated both types equally. In the recent immuno-
histochemical study by Sweeney et al. (11), however, no sig-
nificant difference of MET expression between two subtypes
was found. In their study, MET was expressed in 81.1% and
76.9% of type 1 and type 2 papillary RCC, respectively, which
was consistent with our results. There might be some dis-
crepancies between the changes in molecular level and the
immunoexpression of MET in ours. 
It is of interest that the diffuse and strong expression of
MET was observed in all cases of collecting duct carcinoma,
while the majority of chromophobe RCC and all oncocytomas
did lack in the expression of MET. The molecular character-
istics of renal tumors originating from non-proximal tubules,
including collecting duct carcinoma, chromophobe RCC and
oncocytoma are not well known. Polascik et al. (24) showed
that the loss of heterozygosity of chromosomal arm 3p that
is known to be associated with clear cell RCC was infrequent
in both collecting duct carcinoma and oncocytoma, and con-
cluded that the molecular events contributing to the develop-
ment of non-proximal nephron tumors were distinct from
those associated with renal tumors originating from the prox-
imal tubules. It is unclear why MET expression was different
between in collecting duct carcinoma and in chromophobe
RCC or oncocytoma. We suspected that this might be due
to the difference in the origin of collecting duct carcinoma
and the others. The collecting duct carcinoma is thought to
arise from the distal segment of the collecting duct of Belli-
ni, while renal oncocytoma and chromophobe renal carcino-
ma appears to arise in the cortex from the intercalated cells
of the proximal connecting segment of the collecting ducts
(25, 26). It was not apparent, however, whether the collect-
ing duct of MET overexpression was in the distal segment
of Bellini or the proximal connecting segment of the collect-
ing ducts. Further investigations on the staining localization
in normal renal structure and molecular studies seem to explain
the difference of MET overexpression between collecting duct
carcinoma and chromophobe RCC and oncocytoma.
Most cases (92%) of urothelial carcinoma included in our
study exhibited strong (2+) MET expression. Li et al. showed
MET immunoreactivity in all 49 urothelial carcinomas of the
urinary bladder (27) and Tamatani et al. demonstrated that
HGF stimulated migration and invasion of the rat tumori-
genic urothelial cell lines in vitro (28), while in a study by
Natali et al., all 5 urothelial carcinoma of renal pelvis did not
display MET expression (19). As pointed out by Pisters et al.
(18), this difference may be related to the fact that we used
a polyclonal antibody which could theoretically detect more
epitopes of the MET protein, whereas the antibody used in
the study by Natali et al. (19) was monoclonal antibody against
the extracellular domain of the MET protein. 
We demonstrated that MET expression in clear cell RCC
were correlated with several clinicopathological parameters,
such as infiltrative growth pattern, tumoral necrosis, pelvic
or ureteral involvement, calyceal involvement, and lymphatic
invasion, which were thought to be related to the invasive-
ness or aggressiveness of the tumor (Table 2). In addition,
there was a significant relationship between MET immunore-
activity and the higher Fuhrman’s nuclear grade, which is an
important prognostic factor (p<0.001). These results are com-
parable to those of a few studies demonstrating strong expres-
sion of MET in more than 80% of RCC with higher grades
(18, 19). HGF/SF-MET pathway was reported to enhance
the invasive properties in the chemoinvasion assay and inhibit
Fas-induced apoptosis in vitro (7). In present study, MET
expression was more frequently found in the tumors of ad-
vanced stage (stage 3 or 4) than in localized stage (stage 1 or
2), and all three clear cell RCC with distant metastasis ex-
pressed MET, although it was not statistically significant.
In conclusion, we demonstrated that MET was diffusely
and strongly expressed in papillary RCC, collecting duct car-
cinoma, and urothelial carcinoma of renal pelvis, whereas no
or focal expression of MET was observed in clear cell RCC,
chromophobe RCC and oncocytoma. Diffuse and strong im-
munoexpression of MET in papillary RCC and collecting
duct carcinoma might be helpful in discriminating from the
other subtypes of RCC with tubulo-papillary growth. In clear
cell RCC, there was a significant relationship between MET
expression and high nuclear grade, as well as several clinico-
pathological parameters including infiltrative growth, tumo-
ral necrosis, pelvic or ureteral involvement, calyceal involve-
ment, and lymphatic invasion, implying invasiveness or agg-
ressiveness of the tumor. 
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